Search results for "roe"

showing 10 items of 9822 documents

Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat

2018

0301 basic medicinemedicine.medical_specialtyCancer ResearchLymphomaMice03 medical and health sciences0302 clinical medicineHematology; Oncology; Cancer ResearchInternal medicineTumor MicroenvironmentmedicineAnimalsHumansHeparanase030212 general & internal medicineEnzyme InhibitorsGlucuronidaseHematologyChemistryGeneral MedicineHematologyXenograft Model Antitumor AssaysNeoplasm Proteins030104 developmental biologyOncologyCancer research
researchProduct

Smooth muscle and neural dysfunction contribute to different phases of murine postoperative ileus.

2015

Background Postoperative ileus (POI) is characterized by a transient inhibition of gastrointestinal (GI) motility after abdominal surgery mediated by the inflammation of the muscularis externa (ME). The aim of this study was to identify alterations in the enteric nervous system that may contribute to the pathogenesis of POI. Methods Gastrointestinal transit, contractility of isolated smooth muscle strips and inflammatory parameters were evaluated at different time points (1.5 h to 10 days) after intestinal manipulation (IM) in mice. Immune-labeling was used to visualize changes in myenteric neurons. Key Results Intestinal manipulation resulted in an immediate inhibition of GI transit recove…

0301 basic medicinemedicine.medical_specialtyCarbacholIleusPhysiologyInflammationBiologyEnteric Nervous SystemProinflammatory cytokineContractility03 medical and health sciencesMiceIleusOrgan Culture TechniquesPostoperative ComplicationsInternal medicinemedicineAnimalsEndocrine and Autonomic SystemsGastroenterologyMuscle SmoothSmooth muscle contractionmedicine.diseaseMice Inbred C57BL030104 developmental biologyEndocrinologyAnesthesiaCholinergicEnteric nervous systemFemalemedicine.symptomInflammation MediatorsGastrointestinal Motilitymedicine.drugNeurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
researchProduct

The consumption of snacks and soft drinks between meals may contribute to the development and to persistence of gastro-esophageal reflux disease

2019

Abstract The hypothesis The habit of snacking and drinking soft beverages between breakfast, lunch and dinner, which is very widespread in the western world, could be a primum movens, thereby contributing to the development and subsequent persistence of gastroesophageal reflux disease (GERD). What does the proposed hypothesis based on? The high prevalence of GERD suggests that it is very probably caused by factors, which are intrinsic and widespread in a western lifestyle. Ingesting snacks or imbibing soft drinks between breakfast, lunch and dinner causes additional gastric acid secretion, acid pocket formation, and additional transient lower esophageal sphincter relaxations (TLESRs) with a…

0301 basic medicinemedicine.medical_specialtyCarbonated BeveragesOverweightGastroenterologyEsophageal Sphincter LowerGastric AcidHiatal hernia03 medical and health sciencesEsophagus0302 clinical medicineRisk FactorsInternal medicinePrevalencemedicineHumansObesityEsophagusLife StyleGastro-esophageal Reflux GERD Lifestyle modifications Transient Lower Esophageal Sphincter Relaxation TLESR Snacking and Soft drinks consumption Hiatal Hernia Overweight ObesitySnackingbusiness.industrydigestive oral and skin physiologyRefluxfood and beveragesFeeding BehaviorGeneral MedicineModels TheoreticalOverweightmedicine.diseaseObesitydigestive system diseasesDietHernia Hiatal030104 developmental biologymedicine.anatomical_structureGastroesophageal RefluxGERDGastric acidSnacksmedicine.symptombusiness030217 neurology & neurosurgery
researchProduct

A rare rarity: neuroendocrine tumor of the esophagus

2019

Abstract Esophageal Neuroendocrine tumors (NETs) are rare, aggressive and lacking specific symptoms. This causes a diagnostic delay, worsening the prognosis. Numerous cases are reported in literature, without a consensus on the management. Our aim was to clarify epidemiology, clinical presentation, diagnostic, therapeutic management of esophageal NETs. Extensive literature search identified a total of 226 articles. One hundred twenty-five articles (n = 1676) met the inclusion criteria, showing that: the incidence of esophageal NET varies geographically; men (60–70 years) are more affected; smoking and alcohol abuse are the major risk factors; dysphagia, weight loss, appetite loss are the mo…

0301 basic medicinemedicine.medical_specialtyCarcinoid tumorsesophageal neoplasmsNeuroendocrine tumorsSmall-cell carcinomaGastroenterology03 medical and health sciences0302 clinical medicinegastroenteropancreatic NETInternal medicineEpidemiologymedicinerisk factorsesophageal NEC; gastroenteropancreatic NET; large cell esophageal NEN; MANEC; small cell carcinoma; delayed diagnosis; esophageal neoplasms; humans; neuroendocrine tumors; prognosis; rare diseases; risk factorsEsophagusStage (cooking)esophageal NECdelayed diagnosishumanssmall cell carcinomabusiness.industryLarge cellMANECrare diseasesHematologymedicine.diseaseDysphagia030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesislarge cell esophageal NENprognosismedicine.symptomneuroendocrine tumorsbusiness
researchProduct

Deconvolution of the cellular origin in hepatocellular carcinoma: Hepatocytes take the center stage.

2016

The expression of biliary/progenitor markers by hepatocellular carcinoma (HCC) is often associated with poor prognosis and stem cell-like behaviors of tumor cells. Hepatocellular adenomas (HCA) also often express biliary/progenitor markers and frequently act as precursor lesions for HCC. However, the cell of origin of HCA and HCC that expresses these markers still remains unclear. Therefore, to evaluate if mature hepatocytes give rise to HCA and HCC tumors, and to understand the molecular pathways involved in tumorigenesis, we lineage-labeled hepatocytes by injecting adeno-associated virus (AAV) containing thyroxine-binding globulin (TBG) promoter driven-Cre into RosaYFP mice. Yellow fluore…

0301 basic medicinemedicine.medical_specialtyCarcinoma HepatocellularHepatologyLiver NeoplasmsBiologymedicine.diseaseGastroenterologydigestive system diseasesArticle03 medical and health sciences030104 developmental biologyCellular originInternal medicineHepatocellular carcinomamedicineCancer researchCarcinomaHepatocytesHumansCenter (algebra and category theory)DeconvolutionStage (cooking)Hepatology (Baltimore, Md.)
researchProduct

Reply to: “Performance status in patients with HCC: New kid on the block”

2017

0301 basic medicinemedicine.medical_specialtyCarcinoma HepatocellularPsychometricsHepatologyPerformance statusbusiness.industryLiver NeoplasmsMEDLINESurgery03 medical and health sciences030104 developmental biology0302 clinical medicineBlock (telecommunications)HumansMedicine030211 gastroenterology & hepatologyIn patientbusinessJournal of Hepatology
researchProduct

Hepatocellular carcinoma and direct-acting antivirals: A never ending story?

2017

0301 basic medicinemedicine.medical_specialtyCarcinoma HepatocellularTime FactorsClinical Decision-MakingDIRECT ACTING ANTIVIRALSAntiviral AgentsRisk Assessment03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansHepatologybusiness.industryIncidencePatient SelectionLiver NeoplasmsHepatitis C ChronicHepatologymedicine.diseaseLiver TransplantationTreatment Outcome030104 developmental biologyHepatocellular carcinomaCancer research030211 gastroenterology & hepatologyNeoplasm Recurrence Localbusiness
researchProduct

Systemic treatment of HCC in special populations

2020

Summary Recent years have seen significant progress in the systemic treatment of hepatocellular carcinoma (HCC), including the advent of immunotherapy. While several large phase III trials have provided the evidence for a multi-line treatment paradigm, they have focused on a highly selected group of patients by excluding potentially confounding comorbidities. As a result, high quality evidence for the systemic treatment of HCC in patients with various comorbidities is missing. This review summarises current knowledge on the use of approved medicines in patients with HIV, autoimmune disease, cardiovascular disease, diabetes, fibrolamellar HCC, mixed HCC-cholangiocarcinoma, decompensated cirr…

0301 basic medicinemedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentComorbidityDisease03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicinemedicineHumansMultiple Chronic ConditionsAutoimmune diseaseHepatologybusiness.industryLiver NeoplasmsConfoundingDisease ManagementImmunotherapymedicine.diseasedigestive system diseasesPortal vein thrombosis030104 developmental biologyHepatocellular carcinoma030211 gastroenterology & hepatologyMetabolic syndromebusinessJournal of Hepatology
researchProduct

Biomarkers of Neurodegeneration in Autoimmune-Mediated Encephalitis

2018

Progranulin (PGRN), Total-Tau (t-tau), and Neurofilament light chain (NfL) are well known biomarkers of neurodegeneration. The objective of the present study was to investigate whether these parameters represent also biomarkers in autoimmune-mediated Encephalitis (AE) and may give us insights into the pathomechanisms of AE. We retrospectively examined the concentration of PGRN in the cerebrospinal fluid (CSF) and serum of 38 patients suffering from AE in acute phase and/or under treatment. This AE cohort comprises patients with autoantibodies against: NMDAR (n = 18 patients), Caspr2 (n = 8), Lgi-1 (n = 10), GABAB(R) (n = 1), and AMPAR (n = 1). Additionally, the concentrations of NfL (n = 25…

0301 basic medicinemedicine.medical_specialtyCaspr2 encephalitisLgi-1 encephalitisNMDAR encephalitisGastroenterologyCaspr2 encephalitis; Lgi-1 encephalitis; NMDAR encephalitis; autoimmune encephalitis; neurofilament light chain; progranulin; taulcsh:RC346-429Faculty of Medicine03 medical and health sciences0302 clinical medicineCerebrospinal fluidModified Rankin ScaleMedizinische FakultätInternal medicineprogranulinMedicineddc:6ddc:610taulcsh:Neurology. Diseases of the nervous systemOriginal ResearchAutoimmune encephalitisHippocampal sclerosisbusiness.industryNeurodegenerationAutoantibodyarticleNMDAR encephalitis ; neurofilament light chain ; Caspr2 encephalitis ; autoimmune encephalitis ; progranulin ; Lgi-1 encephalitis ; taumedicine.diseaseautoimmune encephalitis030104 developmental biologyneurofilament light chainNeurologyBiomarker (medicine)Neurology (clinical)business030217 neurology & neurosurgeryEncephalitis
researchProduct

Hepatic benefits of HCV cure

2020

Direct-acting antiviral (DAA)-induced HCV clearance conceivably leads to improved outcomes at all stages of liver disease. However, available data suggest that the maximum measurable benefit is obtained by treating patients before they reach the stage of compensated advanced chronic liver disease (cACLD). Ideally, all patients with chronic hepatitis C should be treated before they develop advanced fibrosis or cirrhosis, since even if sustained virologic response (SVR) reduces the risk of hepatic events (e.g. decompensation and hepatocellular carcinoma [HCC]) and improves survival, further progression of liver disease and adverse outcomes, including hepatic deaths, cannot be entirely avoided…

0301 basic medicinemedicine.medical_specialtyCirrhosisHepatocellular carcinomaPortal venous pressureSurvival.Chronic liver diseaseGastroenterology03 medical and health sciencesLiver disease0302 clinical medicineInternal medicinemedicineDecompensationCirrhosiHepatologybusiness.industryHepatitis Cmedicine.diseaseHepatitis Cdigestive system diseases030104 developmental biologyHepatocellular carcinomaPortal hypertension030211 gastroenterology & hepatologybusiness
researchProduct